ORPHA:48104
Pyoderma gangrenosum
Publications
9,388
Trials
28
Interventional, condition-specific
Researchers
966
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare inflammatory neutrophilic dermatosis characterized by painful cutaneous ulcerations with a violaceous and undermined border affecting the lower extremities; however, any hair-bearing area can be affected.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018824
- MeSH:D017511
- UMLS:C0085652
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
9,388 matched papers (5,251 in last 10 years) Source
- Phenotype characterisedPresent
15 HPO annotations (e.g. Papule; Atrophic scars; Rheumatoid arthritis) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPresent
1 FDA · 1 EMA designations (1 FDA orphan-indication approval) — e.g. gevokizumab Source
- Interventional trialPresent
28 matched on ClinicalTrials.gov (5 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
15
Associated phenotypes · MONDO:0018824
- Papule
- Atrophic scars
- Rheumatoid arthritis
- Fever
- Abnormal blistering of the skin
Showing 5 of 15 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
2
Designations · 1 with FDA orphan-indication approval
- FDA gevokizumabPyoderma Gangrenosum · 2014-02-21 · Not FDA Approved for Orphan Indication
- EMA vilobelimabTreatment of pyoderma gangrenosum · 18/07/2022 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
6 associated chemicals · 42 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Adrenal Cortex Hormones · therapeutic
- Clofazimine · therapeutic
- Silver Sulfadiazine · therapeutic
- Tacrolimus · therapeutic
- Thalidomide · therapeutic
- Cocaine · marker/mechanism
Pathways: NOD-like receptor signaling pathway; TNF signaling pathway; Shigellosis; Pertussis; Tuberculosis; Influenza A; Inflammatory bowel disease (IBD); Cytokine Signaling in Immune system
Literature
Is anyone studying this?
9,388
9,388 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
9,388 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
5,251 in the last 10 years · low confidence
Phrase hits: 9,388 · MeSH hits: 0
Who's working on it?
966
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Ortega-Loayza AG13 papers · 2026
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Papers in Europe PMC - 02Marzano AV7 papers · 2026
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC - 03Zhang R5 papers · 2026
Department of Dermatology, The Second Affiliated Hospital of Wannan Medical University, Wuhu 241000, China.
Papers in Europe PMC - 04Dissemond J4 papers · 2026
Department of Dermatology, Venerology and Allergology, University Hospital Essen, Essen, Germany.
Papers in Europe PMC - 05Downey K4 papers · 2026
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA and.
Papers in Europe PMC - 06Gillespie J4 papers · 2026
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA and.
Papers in Europe PMC - 07Latour E4 papers · 2026
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Papers in Europe PMC - 08Roland-McGowan J4 papers · 2026
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA and.
Papers in Europe PMC - 09
- 10Dini V3 papers · 2026
Department of Dermatology, University of Pisa, Pisa, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
28
interventional trials for this specific condition
28 interventional trials matched this specific condition name; 5 currently recruiting in our sample. 2 trials are registered for pyoderma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
28 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.8th percentile).
low confidence · 95.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
28 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07240649·NOT YET RECRUITING·Emerging Indications for Hyperbaric Oxygen Treatment
Not reviewed·Conditions: Post-COVID-19 Condition · Ulcerative Colitis · Crohn Disease · Calciphylaxis·Matched via name phrase
- NCT06624670·RECRUITING·A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Not reviewed·Conditions: Pyoderma Gangrenosum·Matched via name phrase
- NCT07337564·NOT YET RECRUITING·A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
Not reviewed·Conditions: Pyoderma Gangrenosum·Matched via name phrase
- NCT07444684·NOT YET RECRUITING·A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
Not reviewed·Conditions: Pyoderma Gangrenosum·Matched via name phrase
- NCT06563323·RECRUITING·Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Not reviewed·Conditions: Pyoderma Gangrenosum · Skin Diseases · Wound Heal · Pyoderma·Matched via name phrase
Broader category: pyoderma
2
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 9 · after dedupe 9 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 9 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (9)
- ctis·2024-514306-31-00·Authorised, ongoing·A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy
skipped — LLM skipped (--skip-llm)
- ctis·2024-517155-13-00·Expired·A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome
skipped — LLM skipped (--skip-llm)
- ctis·2024-516277-68-00·Authorised, ongoing·FREE-study; De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring
skipped — LLM skipped (--skip-llm)
- ctis·2023-506250-20-00·Cancelled·A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ADAPTIVE PHASE III TRIAL TO
INVESTIGATE EFFICACY AND SAFETY OF VILOBELIMAB IN THE TREATMENT OF ULCERATIVE PYODERMA
GANGRENOSUM
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15487707·No longer recruiting·Efficacy and safety of a hyaluronic acid-containing cream in the treatment of chronic, venous, or mixed-origin leg ulcers: a prospective, multicenter, randomized, controlled trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98384076·No longer recruiting·Cold atmospheric plasma (CAP) for reduction of bacteria in chronic skin wounds – plasma care study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15014758·No longer recruiting·Surgical glue for the treatment of damaged veins in patients with venous leg ulcers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN64926597·No longer recruiting·Comparing treatments for diabetic foot ulcers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN35898459·No longer recruiting·Study of treatments for pyoderma gangrenosum
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pyoderma gangrenosum — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Pyoderma gangrenosum"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pyoderma gangrenosum"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 28 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"pyoderma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (9388) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T00:13:44.200Z
